Less Ads, More Data, More Tools Register for FREE

Pin to quick picksORPH.L Regulatory News (ORPH)

  • There is currently no data for ORPH

Integumen Debt Conversion

1 May 2019 11:00

RNS Number : 7356X
Venn Life Sciences Holdings PLC
01 May 2019
Β 

1 May 2019

Venn Life Sciences Holdings Plc

("Venn" or the "Company")

Integumen plc ("Integumen") Debt Conversion - Related Party Transaction

Venn Life Sciences, an Integrated Drug Development Partner offering a combination of drug development expertise and clinical trial design and management to pharmaceutical, biotechnology and medical device organisations, announces, that following the approval of Integumen shareholders and under the terms of the Venn Debt Conversion Agreement the debt of Β£421,000 owed by Integumen, has been converted into 30,071,428 new Integumen ordinary shares at a price of 1.4 pence, conditional upon admission.

Separate to this conversion, Venn has sold 42,244,682 ordinary shares for a total consideration of €575,000. Following Admission of the conversion shares referred to above, Venn will hold 30,071,428 ordinary shares.

Venn has agreed that any disposal of Integumen ordinary shares held by them for the two years following Admission will be effected through Integumens broker so as to ensure an orderly market in the ordinary shares.

The debt conversion is a related party transaction for the purposes of Rule 13 of the AIM Rules for companies. As Tony Richardson is Integumens Chairman, the Chief Executive of Venn, and therefore is not considered to be independent for the purposes of considering and negotiating the Venn Debt Conversion Agreement.Β The Directors (other than Tony Richardson) consider, having consulted with Arden Partners plc, the Company's nominated adviser, that the terms of the Venn Debt Conversion Agreement and conversion by Venn are fair and reasonable in so far as its Shareholders are concerned.

Β 

Enquiries:

Venn Life Sciences Holdings plcΒ Tel: +353 1 5499 341Tony Richardson, Chief Executive Officer

Arden Partners plc Tel: +44 (0)2076145900

John Llewellyn-Lloyd, Ruari McGirr, Benjamin Cryer

Davy (ESM Adviser and Joint Broker)Β Tel: +353 (0)1 679 6363Fergal Meegan / Matthew de Vere White (Corporate Finance)

Β 

Β 

DEFINITIONS

The following words and expressions shall have the following meanings in this document unless the context otherwise requires:

Β 

"Venn Debt Conversion Agreement"

the agreement dated 11 April 2019 between (1) the Company and (2) Venn to convert the Venn Debt into the Venn Debt Shares

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
Β 
END
Β 
Β 
MSCSSASUFFUSEEI
Date   Source Headline
11th Jun 20207:00 amRNSMajor New Contract Signed
10th Jun 20205:40 pmRNSHolding(s) in Company
10th Jun 20205:35 pmRNSHolding(s) in Company
10th Jun 20205:30 pmRNSHolding(s) in Company
4th Jun 20207:00 amRNSLaunch of Covid-19 Antibody Testing
29th May 20208:00 amRNSEuronext Growth Dublin Notice
22nd May 202010:53 amRNSResults of Fundraising
22nd May 20207:01 amRNSPrimaryBid.com Offer
22nd May 20207:00 amRNSProposed Fundraising to raise up to £12 million
18th May 20209:05 amRNSSecond Price Monitoring Extn
18th May 20209:00 amRNSPrice Monitoring Extension
18th May 20207:00 amRNSUpdate on antibody test and share price movement
11th May 20207:00 amRNSAppointment of Joint Broker
11th May 20207:00 amRNSNew COVID-19 Antibody Testing Partnership
4th May 20207:00 amRNSMajor New Contract and Directorate Change
23rd Apr 20207:00 amRNSTesting of anti-viral for treating COVID-19
14th Apr 20202:06 pmRNSSecond Price Monitoring Extn
14th Apr 20202:01 pmRNSPrice Monitoring Extension
23rd Mar 20204:43 pmRNSSecond Price Monitoring Extn
23rd Mar 20204:37 pmRNSPrice Monitoring Extension
20th Mar 20202:06 pmRNSSecond Price Monitoring Extn
20th Mar 20202:00 pmRNSPrice Monitoring Extension
16th Mar 20207:00 amRNSPublication of positive results in journal
12th Mar 20203:32 pmRNSHolding(s) in Company
12th Mar 20209:00 amRNSHolding(s) in Company
12th Mar 20208:00 amRNSEuronext Growth Dublin Notice
10th Mar 20207:00 amRNSPublication of Positive Results in Journal
9th Mar 20204:53 pmRNSCompletion of Compulsory Acquisition of Shares
9th Mar 20207:00 amRNSCoronavirus Challenge Study Model
6th Mar 20207:00 amRNSNew Contract
3rd Mar 20208:00 amRNSEuronext Growth Dublin Notice
2nd Mar 20203:25 pmRNSChange in Registered Office
27th Feb 20207:00 amRNSAppointment of new Director
26th Feb 20203:04 pmRNSResult of Rule 15 Offer and Total Voting Rights
21st Feb 20207:00 amRNSInvestor Event Attendance and Presentation
20th Feb 20207:00 amRNSAppointment of Chair of Advisory Board
20th Feb 20207:00 amRNSAppointment of Chair of Advisory Board
13th Feb 20207:00 amRNSAppointment of Group Chief Financial Officer
11th Feb 20208:00 amRNSEuronext Growth Dublin Notice
10th Feb 202011:17 amRNSValue the Markets Webinar
7th Feb 20206:08 pmRNSHolding(s) in Company
7th Feb 20203:42 pmRNSSignificant shareholder
7th Feb 20207:00 amRNSInvestor Event Attendance and Presentation
6th Feb 20209:30 amRNSTotal Voting Rights
6th Feb 20208:00 amRNSEuronext Growth Dublin Notice
6th Feb 20207:00 amRNSUpcoming Investor Events
5th Feb 202011:00 amRNSExercise of Warrants and Issue of Shares
3rd Feb 202010:30 amRNSNew Corporate Presentation
31st Jan 202011:23 amRNSResults of Placing and Subscription
31st Jan 20207:00 amRNSProposed Placing to raise a minimum of £5 million

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.